Turkish Journal of Medical Sciences
Volume 48

Number 6

Article 14

1-1-2018

The diagnostic role of pentraxin-3 in the differential diagnosis of
pleural effusions
FATMA ÇİFTCİ
GÜLDEN BİLGİN
AYŞE NAZ ÖZCAN
ÖZLEM DOĞAN
AYCAN YÜKSEL

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
ÇİFTCİ, FATMA; BİLGİN, GÜLDEN; ÖZCAN, AYŞE NAZ; DOĞAN, ÖZLEM; YÜKSEL, AYCAN; EROL, SERHAT;
ÇİLEDAĞ, AYDIN; and KAYA, AKIN (2018) "The diagnostic role of pentraxin-3 in the differential diagnosis
of pleural effusions," Turkish Journal of Medical Sciences: Vol. 48: No. 6, Article 14. https://doi.org/
10.3906/sag-1710-115
Available at: https://journals.tubitak.gov.tr/medical/vol48/iss6/14

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

The diagnostic role of pentraxin-3 in the differential diagnosis of pleural effusions
Authors
FATMA ÇİFTCİ, GÜLDEN BİLGİN, AYŞE NAZ ÖZCAN, ÖZLEM DOĞAN, AYCAN YÜKSEL, SERHAT EROL,
AYDIN ÇİLEDAĞ, and AKIN KAYA

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol48/iss6/14

Turkish Journal of Medical Sciences

Turk J Med Sci
(2018) 48: 1167-1174
© TÜBİTAK
doi:10.3906/sag-1710-115

http://journals.tubitak.gov.tr/medical/

Research Article

The diagnostic role of pentraxin-3 in the differential diagnosis of pleural effusions
1,

2

3

4

Fatma ÇİFTCİ *, Gülden BİLGİN , Ayşe Naz ÖZCAN , Özlem DOĞAN ,
1
1
1
1
Aycan YÜKSEL , Serhat EROL , Aydın ÇİLEDAĞ , Akın KAYA
1
Department of Chest Disease, School of Medicine, Ankara University, Ankara, Turkey
2
Department of Chest Disease, Ankara Training and Research Hospital, Ankara, Turkey
3
Department of Chest Disease, Atatürk Chest Disease and Chest Surgery Training and Research Hospital, Ankara, Turkey
4
Department of Biochemistry, School of Medicine, Ankara University, Ankara, Turkey
Received: 17.10.2017

Accepted/Published Online: 26.07.2018

Final Version: 12.12.2018

Background/aim: Discrimination of pleural effusion etiology is not always easy in clinical practice. Pentraxin-3 (PTX-3) is a new acutephase protein. The aim of this study was to investigate the role of PTX-3 in the differential diagnosis of pleural effusions.
Materials and methods: This prospective study enrolled all consecutive patients from two tertiary hospitals who underwent diagnostic
or therapeutic thoracentesis. In a cohort of 149 subjects with pleural effusion, including transudates and malignant (MPE), tuberculous
(TPE), and parapneumonic effusion (PPE), serum and pleural effusion PTX-3 concentration measurements were performed using
ELISA. Serum and pleural effusion protein, lactate dehydrogenase, C-reactive protein (CRP), and adenosine deaminase levels were also
assessed.
Results: Of these patients, 34 had transudates, 29 had PPE, 63 had MPE, and 23 had TPE. There was a weak correlation between pleural
effusion PTX-3 level and serum CRP (P < 0.01). There was a significant difference in pleural PTX-3 levels between the exudative effusion
groups (P < 0.01). The median pleural effusion PTX-3 was significantly higher in patients with PPE (11.2 ng/mL, 2–17.8) than MPE (4.7
ng/mL, 1.8–13.9) and TPE (3.1 ng/mL, 2.0–4.1). At a cut-off point of 5.89 ng/mL, PTX-3 had the best discriminatory power for PPE
versus other exudative effusions (sensitivity: 86.2%, specificity: 87.7%). The exudative effusion group had a significantly different pleural
effusion/serum PTX-3 ratio (P = 0.03).
Conclusion: PTX-3 concentration in pleural effusion was elevated without a significant correlation with serum PTX-3 in PPE. These
results may suggest that PTX-3 is a local acute-phase reactant and may allow discrimination of PPE from other exudative effusions.
Key words: Pleural effusion, pentraxin-3, transudates, malignant pleural effusion, tuberculous pleural effusion, parapneumonic effusion.

1. Introduction
Pleural diseases are very common pulmonary conditions,
the main causes of which are primary lung diseases,
systemic diseases, functional organ failure, medication,
and primary pleural pathologies (1). Pleural effusions
occur as a result of increased fluid formation and/or
reduced fluid resorption. Definite physiopathology of
pleural effusion accumulation depends on the underlying
etiology. Pleural effusions may be secondary to increased
pulmonary hydrostatic pressure, reduced plasma oncotic
pressure, increased permeability of the pleura or lymphatic
obstruction, and, rarely, thoracic duct injury. Heart failure,
malignancy, pneumonia, tuberculosis, and pulmonary
embolism are the leading causes of pleural effusions (2).
Pleural effusion analysis can usually identify the
cause of effusion, and thoracentesis should be performed

in all patients with pleural effusion of unknown origin
whose width measures more than 1 cm on chest X-ray or
ultrasound, excluding patients with heart failure (3).
Biochemical, microbiologic, and cytologic analyses of
pleural effusion are the fundamental studies to determine
the etiology of the effusion but it is not easy to find the
main cause every time (4). Therefore, several biomarkers
have been suggested to help differential diagnosis. Pro
calcitonin, amyloid A, and C-reactive protein (CRP) are
well known acute-phase proteins and the results of these
studies have lately been proposed to use for differentiation
of infectious diseases from other origins of pleural effusion
(5). Pentraxin-3 (PTX-3) has also been called tumor
necrosis factor-stimulated gene 14. It is a member of the
pentraxin superfamily (6,7). The secreted human PTX-3 is
a 45-kDa glycoprotein with a 162-amino acid N-terminal
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extension and 202-amino acid C-terminal pentraxin
domain. PTX-3 is a long pentraxin but the structure of its
pentraxin domain is similar to that of pentraxin domains
found in classic short pentraxins. CRP is one of the most
important short pentraxin. All of the short pentraxins are
produced in the liver (6–8). However, PTX-3 is secreted
by different cells (alveolar epithelium, neutrophils,
macrophages, endothelial cells, myeloid-derived dendritic
cells, ovarian granulosa cells, renal mesangial cells,
adipocytes, smooth muscle cells, synovial cells, fibroblasts,
and glial cells) (9). PTX-3 is stimulated and secreted after
proinflammatory stimuli (10). PTX-3 is an acute-phase
biomarker in humans and increases rapidly in blood
during inflammation (6,7). Although the diagnostic role
and prognostic significance of pleural fluid PTX-3 levels
were stressed in two former studies, these points deserve
further clarification (11,12).
In this study we aimed to determine the clinical
significance and diagnostic role of serum and pleural fluid
PTX-3 levels in patients with pleural effusion secondary to
various different etiologic conditions.
2. Materials and methods
2.1. Subjects
This prospective study enrolled all consecutive patients
from two tertiary chest disease clinics who underwent
diagnostic or therapeutic thoracentesis between January
2012 and November 2015. Thoracentesis and laboratory
tests were conducted by the authors at their clinics. The
samples taken for PTX-3 evaluation were centrifuged and
stored at –80 °C in two clinics until the day of operation.
PTX-3 measurement was performed in the biochemistry
laboratory of Ankara University. Tests other than PTX3 measurement were performed immediately after
thoracentesis. This study included patients with pleural
effusion of transudate character, malignant pleural effusion
(MPE), parapneumonic effusion (PPE), and tuberculosisassociated pleural effusion (TPE).
The inclusion criteria included an age of over 18
years and known pleural effusion etiology. The exclusion
criteria included pleural effusion of unknown etiology, i.e.
patients whose disease could not be definitively diagnosed
on the basis of biochemical tests, microbiologic analyses,
cytology, and pathology examination of pleural biopsy
specimens.
2.2. Diagnostic criteria
Pleural effusion was diagnosed using chest X-rays,
computerized tomography (CT) of the chest, and thoracic
ultrasonography. Pleural effusion samples were aspirated
using a fine needle (21 G) and a 50-mL syringe, and blood
samples were drawn simultaneously. The fluid sample was
divided and placed in sterile tubes. Glucose, albumin, total
protein, lactate dehydrogenase (LDH), and adenosine
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deaminase (ADA) levels were measured and recorded in
simultaneously taken pleural effusion and serum samples.
The macroscopic features of the pleural effusion and its pH
level, Gram staining, bacterial culture, and cytology results
were recorded. Serum CRP level was also measured.
Pleural fluid secondary to heart failure was diagnosed
in patients with bilateral pleural effusion on the basis of
typical heart failure symptoms (dyspnea, ankle edema,
fatigue) ±concomitant signs (increased jugular venous
pressure, pulmonary rales, and peripheral edema) and
a left ventricular ejection fraction of less than 50% in
transthoracic echocardiography (13).
Exudative fluids were defined and confirmed according
to Light’s criteria (14). PPE was defined as the acute onset of
symptoms suggestive of a lower respiratory tract infection
and a new infiltrate on chest X-ray (14). PPE was analyzed
in three groups: empyema, noncomplicated PPE, and
complicated PPE. Complicated PPE was described as acidic
pleural fluid (pH <7.20) and suspected infection or positive
Gram stain or positive bacteria culture, and empyema was
described as complicated PPE with pus view in a fluid (15).
A TPE was identified if mycobacterial cultures of pleural
effusion were positive or granulomatous inflammation was
detected on pleural biopsy samples. A pleural effusion was
classified as malignant if malignant cells were detected in
pleural effusion or pleural biopsy samples.
2.3. PTX-3 analysis
Venous blood samples and pleural fluid taken during
the daytime were put into biochemistry tubes. The
samples were then centrifuged at 1500 rpm for 15 min to
separate the sera at room temperature. The samples were
then divided into aliquots using a sterile plastic transfer
pipette, which were put into sterile plastic containers and
stored at –80 °C until required for biochemical analysis.
When an adequate number of samples was collected, all
stored samples were transferred to the laboratory and
simultaneously thawed. According to the manufacturer’s
instructions, serum and pleural fluid PTX-3 measurement
was performed using an enzyme-linked immunosorbent
assay (ELISA) kit (Quantikine ELISA-Human Pentraxin
3; R&D Systems Europe, Ltd., UK) by an operator who
was blinded to each individual’s lung disease or treatment
group. All samples were studied twice.
2.4. Statistical evaluation
The descriptive statistics for categorical variables are
expressed as frequency (percentage) and median (range)
or mean ± standard deviation for continuous variables,
depending on the normality of distribution. Depending
on the normality of data distribution, independent group
comparisons were performed with ANOVA or Kruskal–
Wallis tests. The chi-square test and Fisher’s exact test were
used for categorical variables. The correlation between
pleural effusion PTX-3 level and other pleural fluid
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markers was measured using Spearman’s rank correlation.
A receiver-operating characteristic test was used to
determine optimal cut-off values for pleural effusion
PTX-3 to predict PPE. Sensitivity, specificity, positive
predictive value, negative predictive value, and likelihood
ratios (LRs) with their respective 95% confidence intervals
(CIs) were calculated according to standard formulae. P <
0.05 was considered statistically significant. SPSS 20.0 for
Windows (IBM Corp., Armonk, NY, USA) was used for all
statistical analyses.
3. Results
During the 3-year study period, a total of 217 patients
underwent thoracentesis and their pleural effusion samples
were analyzed. Sixty-eight patients were excluded from

the study: 30 patients with pleural effusion were excluded
because of having unknown pleural effusion etiology, 19
were included in the paramalignant fluid group due to
absence of malignant cells in pleural effusion despite the
patients having a malignancy, 12 cases were classified as
‘miscellaneous’ because they had more than one etiologic
condition, 4 had pulmonary thromboembolism, and 3
patients with rheumatic arthritis had numbers too low to
conduct statistical analyses (Figure 1).
The study group included 149 subjects (97 males and
52 females) with a mean age of 66.67 ± 11.47 years. Of
these, 34 (22.8%) had transudates due to heart failure, 29
(19.5%) had PPE, 63 (42.3%) had MPE, and 23 (15.4%)
had TPE. Sixty-three patients with MPE had effusions
secondary to lung cancer (n = 48), breast cancer (n = 5),

Plueral fluid and serum samples
were taken from 217 subjects
aged > 18 years during 3 years
study period
68 patients excluded:
30 unknown etiology
19 paramalignant
12 miscellano us
4 pulmonary
thromboembolism
3 rheumatoid arthritis

Pleural fluid and
serum samples of
149 cases were
included in the study

Malignant
pleural
effusions
63 (42.3%)

Lung
cancer
48

Adenocarcinoma
23

Small cell
carcinoma
15

Breast
cancer
5

Renal cell
cancer
4

Hematologic
malignancies
3

Transudate
Effusions
34 (22.8%)

Mesothelioma
3

Tuberculous
effusions
23 (15.4%)

Malignant
melanoma
1

Squamous cell
carcinoma
9

1

Parapneumonic
effusion
29 (19.5%)

Empyema
4

Complicated
parapneumonic
effusion
9

Noncomplicated
parapneumonic
effusion
16

Figure 1. Flow chart of the study showing the inclusion and exclusion criteria.
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renal cell cancer (n = 4), hematologic malignancies (n = 3),
mesothelioma (n = 3), and malignant melanoma (n = 1).
Primary lung tumors responsible for pleural effusion were
adenocarcinoma (n = 23), small cell carcinoma (n = 15),
and squamous cell carcinoma (n = 9).
Among the patients with PPE, 4 had empyema,
9 had complicated parapneumonic PE, and 16 had
noncomplicated parapneumonic PE. Although there was
no correlation between pleural fluid etiology and the
patient age, sex, and body mass index (BMI), the rate of
cumulative smoking history of patients with MPE was
significantly higher than in the other exudative effusion
groups (P = 0.03) (Table 1).
Table 2 shows the comparison of pleural effusion PTX3, ADA, and serum PTX-3 and CRP levels between the
different etiological groups of pleural effusion. There was
a statistically significant but weak correlation between
pleural effusion PTX-3 level and serum CRP level (r =
0.425, P < 0.01).
The median pleural effusion PTX-3 level of the whole
study group was 4.8 ng/mL (range: 1.0–17.8 ng/mL) and
the median PTX-3 level of the exudative fluid group was
5.4 ng/mL (range: 2.0–17.8 ng/mL). The PTX-3 level in
exudative pleural effusion samples significantly differed by
pleural effusion etiology (P < 0.01). The median pleural
effusion PTX-3 was significantly higher in patients with
PPE (11.2 ng/mL; range: 2–17.8 ng/mL) than MPE (4.7 ng/
mL; range: 1.8–13.9 ng/mL) and TPE (3.1 ng/mL; range:
2.0–4.1 ng/mL) (Figure 2). Pleural effusion PTX-3 levels’
diagnostic accuracy for identifying PPE was measured
using area under the receiver-operating characteristic curve
analysis (area under the curve of 0.88). At a cut-off point of
5.89 ng/mL, PTX-3 had the best discriminatory power for
PPE versus other exudative effusions (sensitivity: 86.2%,
specificity: 87.7%) (Figure 3). The negative predictive
value of PTX-3 for PPE was found as 89%. There were no
significant differences between the pleural effusion PTX3 levels of empyema and complicated parapneumonic PE

cases and noncomplicated parapneumonic PE cases (13.4
ng/mL and 10.2 ng/mL, respectively; P > 0.05). Pleural
effusion PTX-3 level was not significantly correlated with
serum PTX-3 level. Serum PTX-3 level had no significant
correlation to exudative pleural effusion etiology. The
pleural effusion/serum ratios of PTX-3, protein, and LDH
levels were also calculated. The exudative effusion group
had a significantly different pleural effusion/serum PTX3 ratio (P = 0.03), whereas no significant difference was
found for the other parameters (Table 2).
4. Discussion
PTX-3 plays a key role in the early stages of inflammation
(16–21). Based on this information, pleural effusion and
serum PTX-3 levels were studied in pleural effusion of
different etiologies. The pleural fluid PTX-3 level was
higher in the whole exudative pleural fluid than the
transudative fluid. An etiology-based comparison of the
serum and pleural effusion PTX-3 levels revealed that the
PTX-3 level was significantly higher in PPE compared with
other exudative effusion groups. The results of our study
were comparable with those of the other studies that
investigated PTX-3 levels and correlations in exudative
pleural effusions (11,12).
The present study showed that serum PTX-3 levels of
exudative pleural effusion were not significantly different,
with the exception of the PPE. There was a significant
difference between serum CRP levels but no significant
difference between serum PTX-3 levels. These results
suggest that PTX-3 is an inflammatory acute-phase
biomarker produced at the site of infection; different
from CRP, it may be a better biomarker in pointing to
local inflammation. CRP, rather than PTX-3, is primarily
produced in the liver after stimulation of IL-6 and TNF-α.
However, PTX-3 is produced by a variety of cells and
tissues, especially dendritic cells and macrophages, in
response to inflammatory cytokines (21–23). Higher levels
of CRP in pleural fluid may simply reflect higher systemic

Table 1. Comparison of the general characteristics of the study population based on pleural effusion etiology.

Transudate
n = 34

Exudates
n = 115

P

MPE
n = 63

PPE
n = 29

TPE
n = 23

71.4 ± 13.5

71.3 ± 10.7

66.2 ± 12.7

67.1 ± 7.2

NS

BMI, kg/m

27.3 ± 4.5

24.4 ± 8.4

25.3 ± 10.3

23.1 ± 4.4

NS

Cumulative smoking, pack-years

12.3 ± 10.4

35.2 ± 20.3

25.4 ± 12.2

20.24 ± 10.8

0.03

Age, years
2

Values are presented as mean ± SD.
MPE, Malignant pleural effusion; PPE, parapneumonic pleural effusion; TPE, tuberculous pleural effusion.
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Table 2. Comparison of serum and pleural fluid findings based on pleural fluid etiology.

Transudate
n = 34

Exudates
n=115
MPE
n = 63

PPE
n = 29

TPE
n = 23

P

Pleural effusion PTX-3 level, ng/mL

1.9 (1.01–3.06)

4.7 (1.8–13.9)

11.2 (2.0–17.8)

3.1 (2.0–4.1)

< 0.01

Serum PTX-3 level, ng/mL

2.7 (1.1–4.65)

3.2 (1.13–5.6)

4.3 (1.5–8.3)

3.5 (1.3–6.3)

NS

CRP, mg/L

5.3 ± 2.2

18.6 ± 11.3

75.6 ± 34.2

62.4 ± 51.2

< 0.01

ADA (PE), IU/L

10.4 ± 0.5

28.2 ± 6.6

20.3 ± 4.7

45.6 ± 7.3

0.04

PTX-3 rate

1.2 (0.3–1.5)

2.9 (0.6–3.5)

3.9 (0.2–4.6)

2.3 (0.3–1.6)

0.03

Protein rate

0.3 (0.2–0.5)

0.7 (0.5–1.0)

0.7 (0.6–1.1)

0.9 (0.5–1.3)

NS

LDH rate

0.4 (0.3–0.6)

0.8 (0.6–1.1)

0.9 (0.5–1.0)

0.8 (0.6–1.2)

NS

Pleural effusion/serum rates

Values are presented as median (range) or mean ± SD.
PTX-3, Pentraxin-3; MPE, malignant pleural effusion; PPE, parapneumonic pleural effusion; TPE, tuberculous pleural effusion; CRP,
C-reactive protein; LDH, lactate dehydrogenase; ADA, adenosine deaminase; PTX-3 rate, pleural effusion PTX-3 level/serum PTX-3
level; protein rate, pleural effusion protein level/serum protein level; LDH rate, pleural effusion LDH level/serum LDH level.
P-value shows difference between exudative effusions.

Figure 2. Box-plot graphics showing pentraxin-3 (PTX-3) concentrations in pleural fluids
associated with different etiologies (MPE, malignant pleural effusions; PPE, parapneumonic
effusions; TPE, tuberculous pleural effusions).

levels because CRP is primarily produced in the liver and
may arrive in the pleural space from plasma diffusion
(24). This may suggest that CRP is unlikely to reflect
local inflammation, but rather the spread of systemic

inflammation (25). Another reason why PTX-3 may be
a better indicator of local inflammation is the fact that
lung epithelial cells, endothelial cells, and leukocytes are
important sources of PTX-3 production when stimulated
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Figure 3. The receiver-operating characteristics (ROC) curves drawn to differentiate pleural
effusion and serum pentraxin-3 (PTX-3) concentrations of the parapneumonic effusion
(PPE) group from other etiologies of exudative pleural fluid.

(20,21). The level of PTX-3 was elevated in patients with
acute lung injury and acute respiratory distress syndrome
(22).
We found no significant differences between the MPE,
TPE, and PPE groups with regard to pleural effusion
protein, glucose, and LDH levels. Moreover, the pleural
effusion to serum protein and LDH ratios, which are
components of Light’s criteria, were not different among
the exudative effusion groups, whereas the PTX-3 ratio
was significantly greater in the PPE group. This suggests
that the PTX-3 effusion/serum ratio may be of value in
differential diagnosis, and other biochemical tests have no
role in the differential diagnosis of exudative effusions.
Several studies suggested that PTX-3 was a promising
biomarker for acute inflammation processes (16,18,19,21).
Alveolar PTX-3 was an early marker of microbiologically
confirmed pneumonia with better diagnostic accuracy
than other biomarkers. Mauri et al. reported that PTX3 levels in BAL fluid might have a superior diagnostic
accuracy for pneumonia than other current biomarkers
and clinical markers in critically ill intubated patients (23).
In experimental pneumonia, PTX-3 has been shown to
identify various microorganisms (i.e. bacteria, viruses, and
fungi) and to improve their clearance, primarily by control
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of neutrophil recruitment (20). Serum PTX-3 levels
correlate with clinical severity of many infectious diseases
in humans (24). For example, serum PTX-3 is raised in
the severe forms of community-acquired and ventilatorassociated pneumonia (25,26). PTX-3 measurement
promotes discrimination of PPE from other exudative
effusions (24).
There are some limitations of this study. First, its
modest sample size prevented us from performing more
precise statistical analyses and evaluating the subgroups of
MPE and PPE groups. No specific test was used to assess
the correlation between PTX-3 level and disease severity.
Testing for other inflammatory markers and making
statistical comparisons might have strengthened our
results.
In conclusion, pentraxin-3 could be a favorable
acute-phase inflammatory mediator to differentiate
PPE from other causes of pleural fluids. Pentraxin-3 is a
promising biomarker involved in the local recognition of
inflammation. In PPE, an increased pleural fluid PTX-3
level without a significant increase in serum PTX-3 level
may reflect a more severe local inflammation than those
occurring in MPE or TPE.
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